APOE - 跨阿尔茨海默氏病连续体的相关海马缩轨迹:系统性审查,元分析和纵向验证
Minnuo Cai1,2, Hang Lei1, Yuetong Zhang1
1Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China.
medRxiv : the preprint server for health sciences
|December 18, 2025
概括
只有当粉样β存在时,APOE-ε4基因才能加速神经退行. 这一发现表明,将粉样蛋白状况与APOE基因型相结合,对于预测疾病进展至关重要.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 生物标志物 生物标志物
背景情况:
- 在海马缩中Apolipoprotein E (APOE) ε4等位基因的作用仍在争论中.
- 调查APOE-ε4是否作为静态危险因子或粉样β (Aβ) 依赖的神经退行症调节器至关重要.
研究的目的:
- 确定APOE-ε4在海马缩中的特定作用.
- 为了阐明APOE-ε4之间的相互作用,粉样蛋白病理和神经退行.
主要方法:
- 18项研究 (N=3,781) 的系统元分析与纵向验证相结合.
- 在NACC和ADNI队列中使用了线性混合效应模型 (N>5,000).
- 生物标志物分层被用来测试基因病理相互作用.
主要成果:
- 分析证实了APOE-ε4载体的显著缩,但具有很高的异质性.
- 纵向分析显示,Aβ阴性载体和非载体的缩率相似.
- Aβ阳性极大地加快了载体的缩,同胞细胞的衰减速度超过三倍.
结论:
- APOE-ε4是神经退行症的条件加速剂,依赖于Aβ病理.
- APOE-ε4的有害作用取决于Aβ的存在.
- 临床风险分层应包括粉样蛋白状况和APOE基因型,以准确预测结构性进展.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.7K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.8K
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752